Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, “All continued discussions between Meda and Mylan have been terminated without further actions.”
In June 2013, Meda denied that it was in talks to be acquired by Sun Pharmaceuticals.
Meda’s products include Dymista azelastine/fluticasone nasal spray, Astepro azelastine nasal spray, a formoterol DPI, and a budesonide DPI. Meda also acquired Acton Pharmaceuticals and its Aerospan flunisolide MDI in 2013.
Read the Meda press release.
